VANCOUVER, British Columbia--(BUSINESS WIRE)--July 7, 2006--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has provided additional details and explanation of recently published scientific data that indicates significant long term safety and health advantages of MIVT’s programs to develop a new class of better and safer cardiovascular stents.
